Kventiax

Quetiapine, the active ingredient in Kventiax, is an atypical antipsychotic presented as an oral formulation for oral use. It treats schizophrenia, bipolar disorder (manic episodes) and major depressive disorder as adjunct therapy in adult patients.

GNH USA supplies Kventiax as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Quetiapine acts on multiple neurotransmitter pathways to manage serious psychiatric conditions.

- Schizophrenia: reduces psychotic symptoms such as delusions and hallucinations. - Bipolar disorder (manic episodes): stabilizes mood and decreases the frequency of manic episodes. - Major depressive disorder (adjunct therapy): enhances response to standard antidepressant treatment.

Common Side Effects: - Drowsiness: feeling of sleepiness or fatigue. - Dry mouth: reduced salivation. - Constipation: decreased bowel movements. - Weight gain: increase in body weight.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: rare but potentially life‑threatening reaction. - Tardive dyskinesia: persistent involuntary movements. - Agranulocytosis: severe reduction in white blood cell count.

When prescribing Kventiax, clinicians should consider several safety measures. - Cardiovascular monitoring: assess blood pressure and heart rate due to possible orthostatic hypotension. - Metabolic assessment: monitor weight, glucose and lipid levels regularly. - CNS depression: caution when combined with other sedatives or alcohol. - Elderly patients: increased sensitivity to sedation and falls; start at low dose. - Pregnancy and lactation: use only if benefits outweigh risks; discuss with prescriber. - Store at ambient temperature: keep below 25°C in original container, protect from moisture and light.

Quetiapine may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase quetiapine plasma levels. - CNS depressants (e.g., benzodiazepines, opioids): can enhance sedation and respiratory depression. - Antihypertensive agents: additive orthostatic hypotension.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness. - Anticholinergic drugs: may worsen dry mouth and constipation. - Lithium: monitor serum levels due to potential neurotoxicity.